Pharma Pulse: Navigating the NDC Shift and the Dark Side of Serialization

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast in which we bring you the latest insights shaping patient access and healthcare innovation. I'm your host, and let's get into today's headlines.

• First, the industry is bracing for a "Y2K-style" transition as the FDA moves to a standardized 12-digit National Drug Code by 2033. This shift goes far beyond a simple labeling update; it impacts the entire infrastructure of pharmaceutical transactions, including reimbursements, electronic health records, and retail software. Stakeholders are warned that early impact assessments are critical to prevent massive supply chain disruptions, especially for companies managing thousands of SKUs.
• Next up, we explore the "dark side" of product security, where experts argue that being "serialized" does not mean being "secure". While serialization meets regulatory traceability requirements, 2D barcodes can still be replicated and exploited by counterfeiters. To move beyond mere compliance, manufacturers are urged to adopt layered security strategies that verify the physical product’s intrinsic features rather than relying solely on printed digital identifiers.

That's it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access, visit pharmaceuticalcommerce.com. Thanks for listening—until next time, stay well and stay informed.
You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.